 |
NIH celebrates FDA approval of long-acting injectable drug for HIV prevention
NIH | December 21, 2021
|
|
FDA Approves APRETUDE (cabotegravir) for HIV-1 Pre-Exposure Prophylaxis
FDA | December 20, 2021
|
|
HIV Drug Resistance Report - November 2021
ReliefWeb | November 24, 2021
|
|
Injectable HIV treatment for patients in UK | HIV AIDS | Health News
YouTube | November 22, 2021
|
|
Clinics will need new systems to administer injectable HIV therapies, says Canadian early adopter
Aidsmap | November 5, 2021
|
|
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
NIH | November 4, 2021
|
|
NATAP | October 26, 2021
|
|
Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results
AIDS. 2021 Oct 13. doi: 10.1097/QAD.0000000000003085.
|
|
TAG’s 2021 Pipeline Report: The Latest in HIV and HCV R&D
Treatment Action Group | October 2021 |
|
ViiV | 28 September 2021
|
|
Antivir Ther. 2020;25(1):21-32. doi: 10.3851/IMP3346
|
|
FDA Approves Pfizer Booster Shots for Seniors, High-Risk Americans
docwirenews | September 23, 2021 |
|
Agents Used in Antiretroviral Therapy
Clinical Care Options | September 2021
|
|
Researchers advance the use of nanoparticles to deliver HIV/AIDS drugs to the brain
FIU News | September 17, 2021
|
|
First-in-Class NRTTI Demonstrates Potential as Long-Acting Oral PrEP Against HIV
Contagionlive.com | September 10, 2021
|
|
Open Forum Infect Dis. 2021 Aug 25;8(9):ofab439. doi: 10.1093/ofid/ofab439. eCollection 2021 Sep.
|
|
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV
AIDSinfo | August 16, 2021 |
|
Direct oral anticoagulants versus warfarin in people living with human immunodeficiency virus
Int J STD AIDS. 2021 Jul 23;9564624211031728. doi: 10.1177/09564624211031728
|
|
Changes to the Epclusa product label for use in pediatrics
FDA | June 2021
|
|
Changes to the Mavyret product labeling for use in pediatrics
FDA | June 2021
|
|
At Last, Generic HIV Prevention Drugs Promise Savings And Access—But Also Reveal Precarious Financing
Health Affairs | May 20, 2021
|
|
How modern medication has extended the life span of people with HIV over the past 40 years
California News Times | May 2021
|
|
Six drugmakers are in violation of 340B statute, says HRSA
Healthcare Finance News | May 18, 2021
|
|
Clinical Insights into New Treatment Options for HIV: Cabenuva and Vocabria
Pharmacy Times | May 10, 2021
|
|
ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
Business Wire | May 4, 2021
|
| |
|
|
|
Still Protected! Medicare's Six Protected Drug Classes Policy Survives Trump's Attack
ADAP Advocacy Association | April 29, 2021
|
|
Revisions to the Trogarzo (ibalizumab-uiyk) product labeling
FDA | April 26, 2021
|
|
CANN Celebrates Biden Administration Protecting Medicare Part D
Community Access national Network | March 2021
|
|
Certain HIV Meds May Trigger Weight Gain
WebMD | March 16, 2021
|
|
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
Business Wire | March 15, 2021
|
|
Another HIV Tivicay Birth Outcome: Better Infant Survival
Medscape | MARCH 15, 2021
|
|
PAF’s Co-Pay Relief Expands Assistance to Cover Insurance Premiums (including HIV/AIDS Fund).
ADAP | MARCH 11, 2021
|
|
CROI: GILEAD'S INVESTIGATIONAL LENACAPAVIR DEMONSTRATES SUSTAINED LONG-ACTING EFFICACY THROUGH WEEK 26 IN DATA PRESENTED AT CROI
NATAP | CROI 2021 March 6-10 |
|
CROI: PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254
NATAP | CROI 2021 March 6-10 |
|
CROI: GSK3640254 IS A NOVEL MATURATION INHIBITOR WITH AN OPTIMIZED VIROLOGY PROFILE
NATAP | CROI 2021 March 6-10 |
|
CROI: NNRTI MK-8507 SELECTS V106 MUTATIONS, ACTIVE AGAINST COMMON NNRTI MUTATIONS
NATAP | CROI 2021 March 6-10 |
|
CROI: CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS
NATAP | CROI 2021 March 6-10 |
|
CROI: ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR
NATAP | CROI 2021 March 6-10 |
|
CROI: POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH
NATAP | CROI 2021 March 6-10 |
|
Revisions to TRIUMEQ and DOVATO labeling
FDA | March 2, 2021
|
|
Op-ed: Six Protected Classes and Protecting People with HIV
plus | February 26, 2021
|
|
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months
ViiV Healthcare | February 24, 2021
|
|
Ask the Doctors: New HIV treatment administered monthly
Lompoc Record | February 18, 2021
|
|
Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
aidsinfo | February 10, 2021 |
|
FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection
ViiV Healthcare | January 21, 2021
|
|
MAT Provides Patients with More Transparency Around Medicine Costs
ADAP Advocacy Association | January 21, 2021
Emma Berry, Advocacy & Strategic Alliances, Pharmaceutical Research and Manufacturers of America (PhRMA).
|
|
Tivicay approved in Europe in new dispersible tablet for children with HIV
pharmaphorum | January 14, 2021
|
|
Valganciclovir and Ganciclovir Effective for HIV-Associated CMVR in Low- and Middle-Income Countries
Infectious Disease Advisor | January 11, 2021
|
|
Many health plans now must cover full cost of expensive HIV prevention drugs
Duluth News Tribune | January 10, 2021
|
| |
|
|
